Episodios

  • Stryker's Kevin Lobo, Dexcom's Kevin Sayer talk diversity, COVID-19; also more on Medtronic deal

    Stryker's Kevin Lobo, Dexcom's Kevin Sayer talk diversity, COVID-19; also more on Medtronic deal
    Jun 19 2020
    This week’s DeviceTalks Weekly podcast episode talks with industry leaders about improving worker diversity and developing new ways to treat COVID-19 patients. Kevin Lobo, chairman and CEO of Stryker, explains how his company – and the industry group AdvaMed – has been working to increase diversity of its workforce, particularly in senior and sales positions. Lobo is serving a two-year term as chairman of AdvaMed. In this interview, Lobo speaks specifically to how Stryker is tracking progress, where it has come up short, and how it’s working to help workers identify their own biases. Lobo also says Stryker is poised to regain momentum after the pandemic. Next, Kevin Sayer, executive chairman, CEO and president of Dexcom, says the company’s continuous glucose monitors are finding a home in hospitals as they help monitor the health of COVID-19 patients. Sayer says the company’s monitors have helped keep patients, especially diabetics, off ventilators and allowed them to get discharged more quickly. What’s next for Dexcom? “We think this is an important market for us, not just COVID-wise,” Sayer says. Finally, Raj Denhoy, equity research analyst at Jefferies, breaks down private equity group Blackstone’s investment in Medtronic’s diabetes line. Why would the medtech giant take outside money? Is this something we’ll see more of in medtech? Don’t miss an episode! Subscribe to DeviceTalks Weekly on your podcast players.
    Más Menos
    40 m
  • Cala Health CEO Renee Ryan Brings Business Building Insights to Bioelectronic Medicine Startup

    Cala Health CEO Renee Ryan Brings Business Building Insights to Bioelectronic Medicine Startup
    Jun 12 2020
    DeviceTalks Weekly: Ep. 13 – Cala Health CEO Renee Ryan Brings Business Building Insights to Bioelectronic Medicine Startup In this week’s episode of DeviceTalks Weekly, Tom Salemi, editorial director of DeviceTalks events and content, visits with Renee Ryan, the CEO of neuromodulation startup Cala Health. Ryan came to Cala from the venerable medtech investor Johnson & Johnson Development Corp., where she made over 15 investments helping to create companies including Auris Surgical, Cala and digital surgery play Verb Surgical, J&J’s joint venture with Verily. “I really set my mind to [asking] was there a way we could create our own opportunities,” she said of her eight years as the corporate investor. We ask Ryan about her move into medtech investing from investment banking as well as the “secret power” that helped her succeed as an investor and an executive. We’ll also discuss the unique commercial strategy Cala is employing as it begins rolling out its Cala Trio, a bioelectronic device developed to treat essential tremor. The interview was conducted in February. What role will tech companies play in medtech’s future? Did Verb Surgical meet her expectations? As CEO how do you manage investor syndicates with multiple corporate investors? Can Cala secure reimbursement and create a new market for tremors? What grade did she skip as a child? Don’t miss an episode! Subscribe to DeviceTalks Weekly on your podcast players.
    Más Menos
    33 m
  • DTW's Commencement Speaker- Todd Brinton, MD, Edwards Lifesciences on building a career in medtech

    DTW's Commencement Speaker- Todd Brinton, MD, Edwards Lifesciences on building a career in medtech
    May 29 2020
    In this week’s DeviceTalks Weekly podcast, we attempt to deliver heartfelt and hard won advice in a sort of commencement address by Todd Brinton, MD, Corporate Vice President, Advanced Technology and Chief Scientific Officer of Edwards Lifesciences. Dr. Brinton sits down with host Tom Salemi to share his path into Medtech. Brinton shares great advice for anyone looking for a new career or opportunity in medtech. NOTE: This conversation was recorded in March, prior to the full impact of the COVID-19 pandemic.
    Más Menos
    49 m
  • Medtronic is buckling up and ready to buy

    Medtronic is buckling up and ready to buy
    May 22 2020
    DeviceTalks Weekly: Ep. 11 – Medtronic is buckling up and ready to buy In this week’s episode of DeviceTalks Weekly, we dip into Medtronic’s quarterly call to hear why company executives feel the medtech sector is already rebounding. The global giant also intends to start using its vast cash reserves to bolster its bottomline through M&A. We’ll also talk with Jeff Champagne of MPR about medtech’s need for speed. He’ll be leading a discussion on this subject and more on the upcoming DeviceTalks Tuesdays. Don’t miss an episode! Subscribe to DeviceTalks Weekly on your podcast players.
    Más Menos
    14 m
  • How do medtech investors, CEOS manage portfolio companies going forward?

    How do medtech investors, CEOS manage portfolio companies going forward?
    May 15 2020
    DeviceTalks Weekly: Ep. 10 – How do medtech investors, CEOS manage portfolio companies going forward? In this week’s episode of DeviceTalks Weekly, we talk with two successful starters of medtech companies about how they’re building and maintaining their medtech portfolios during this pandemic landscape. Our guests this week are… • Justin Klein, MD, managing partner, Vensana Capital • Duke Rohlen, chairman, Ajax Health Together, Klein and Rohlen have created, backed and sold medtech companies that have generated billions. Klein, formerly of New Enterprise Associates, now co-manages his own venture firm, Vensana Capital. He previously served on the board of directors of Cartiva (acquired), ChromaCode, CV Ingenuity (acquired), EPIX Therapeutics (acquired), FIRE1, GPB Scientific, Intact Vascular, Metavention, Personal Genome Diagnostics, PhaseBio Pharmaceuticals (IPO), Relievant Medsystems, Senseonics (IPO), Topera (acquired), Ulthera (acquired), Vertiflex (acquired), Vesper Medical, and VytronUS (acquired). Rohlen, who leads a holdings company backed by private equity giant KKR, previously served as chairman and CEO of EPIX, Co-founder, Chairman and CEO of Spirox, Inc (sold to Entellus Medical) and co-founder and CEO of CV Ingenuity. He was also president of Fox Hollow before it was acquired by EV3. In this podcast we’ll learn how VCs are looking at investment opportunities in this market • Are they making new investments? • What impact is this having on valuation? • Do VCs give stronger consideration to new concerns like supply chain? • When will they get clinical trials up and running? Don’t miss an episode! Subscribe to DeviceTalks Weekly on your podcast players.
    Más Menos
    37 m
  • DeviceTalks Weekly: Ep. 9 – What’s the state of the Medtech job market?

    DeviceTalks Weekly: Ep. 9 – What’s the state of the Medtech job market?
    May 8 2020
    In this week’s episode of DeviceTalks Weekly, Tom Salemi speaks with two executive recruiters about what they see in the medtech market. Over the past month, we’ve seen several medtech companies – big and small – cutting jobs and reducing hours but what does this mean long-term. In this podcast we’ll identify a few companies that are hiring, but we’ll talk in-depth with the recruiters about… • How bad is the current market? • What’s the likelihood for recovery? • What skills are in greater demand? • What can people do to strengthen their hand? Guests are: • David L. Vied, global sector leader, Global Sector Leader, Medical Devices and Diagnostics, Korn Ferry • Giovanni Lauricella, vice president, medtech practice-lead, The Mullings Group Don’t miss an episode! Subscribe to DeviceTalks Weekly on your podcast players.
    Más Menos
    32 m
  • AdvaMed‘s Scott Whitaker on pandemic readiness, Jon Norris of SVB shares Q1 VC data

    AdvaMed‘s Scott Whitaker on pandemic readiness, Jon Norris of SVB shares Q1 VC data
    May 1 2020
    DeviceTalks Weekly: Ep. 8 – AdvaMed‘s Scott Whitaker on pandemic readiness, Jon Norris of SVB shares Q1 venture capital investment data In this week’s episode of DeviceTalks Weekly, Scott Whitaker, CEO of AdvaMed, shares concerns he had over how the federal government would work with the medtech industry during the pandemic crisis. Does he feel the medtech industry was treated fairly? How does he see the federal government and medtech industry working together in the future? He answers those questions and more. In our second interview, Jonathan Norris, managing director of Silicon Valley Bank, shares first-quarter data for medtech venture investments. The results might surprise you. Guests are: • Scott Whitaker, CEO, AdvaMed • Jonathan Norris, managing director, Silicon Valley bank Don’t miss an episode! Subscribe to DeviceTalks Weekly on your podcast players.
    Más Menos
    39 m
  • DeviceTalks Weekly: Ep.7 – Edwards, Employment News, Update on Clinical Trials from Avania

    DeviceTalks Weekly: Ep.7 – Edwards, Employment News, Update on Clinical Trials from Avania
    Apr 25 2020
    In this week’s episode of DeviceTalks Weekly, Tom Salemi and Chris Newmarker stare at each other through the Zoom lens while talking about the positive news from Baxter and Conformis, the hopeful projections from Edwards, and the cautionary tone from Medtronic. We also interview Mark McIlduff, general manager, US, at the newly named CRO, Avania on the state of clinical trials. What changes might we expect in the future? Mark brings great insights. Guests are: • Mark McIlduff, general manager, US, Avania Don’t miss an episode! Subscribe to DeviceTalks Weekly on your podcast players.
    Más Menos
    34 m
adbl_web_global_use_to_activate_webcro768_stickypopup